156 related articles for article (PubMed ID: 8549096)
1. The effect of auranofin and sulphasalazine therapy on circulating levels of interleukin 6 in rheumatoid arthritis patients.
Crilly A; Capell HA; Watson J; Madhok R
Clin Rheumatol; 1995 Sep; 14(5):561-5. PubMed ID: 8549096
[No Abstract] [Full Text] [Related]
2. Prospective trial comparing the use of sulphasalazine and auranofin as second line drugs in patients with rheumatoid arthritis.
Porter D; Madhok R; Hunter JA; Capell HA
Ann Rheum Dis; 1992 Apr; 51(4):461-4. PubMed ID: 1350192
[TBL] [Abstract][Full Text] [Related]
3. Production of interleukin-6 by monocytes isolated from rheumatoid arthritis patients receiving second-line drug therapy.
Crilly A; Madhok R; Watson J; Capell HA; Sturrock RD
Br J Rheumatol; 1994 Sep; 33(9):821-5. PubMed ID: 7915945
[TBL] [Abstract][Full Text] [Related]
4. Serum concentrations of soluble interleukin 2 receptor in patients with rheumatoid arthritis: effect of second line drugs.
Crilly A; Madhok R; Watson J; Capell HA
Ann Rheum Dis; 1993 Jan; 52(1):58-60. PubMed ID: 8093995
[TBL] [Abstract][Full Text] [Related]
5. Circulating cytokine levels in patients with rheumatoid arthritis: results of a double blind trial with sulphasalazine.
Danis VA; Franic GM; Rathjen DA; Laurent RM; Brooks PM
Ann Rheum Dis; 1992 Aug; 51(8):946-50. PubMed ID: 1358037
[TBL] [Abstract][Full Text] [Related]
6. Second line (disease modifying) treatment in rheumatoid arthritis: which drug for which patient?
Capell HA; Porter DR; Madhok R; Hunter JA
Ann Rheum Dis; 1993 Jun; 52(6):423-8. PubMed ID: 8100702
[TBL] [Abstract][Full Text] [Related]
7. Suppression of circulating interleukin-6 concentrations is associated with decreased endothelial activation in rheumatoid arthritis.
Dessein PH; Joffe BI
Clin Exp Rheumatol; 2006; 24(2):161-7. PubMed ID: 16762151
[TBL] [Abstract][Full Text] [Related]
8. IL-6 and soluble IL-2 receptor in rheumatoid arthritis patients treated with second line drugs.
Watson J; Crilly A; Madhok R; Capell H; Sturrock R
Biochem Soc Trans; 1992 May; 20(2):138S. PubMed ID: 1356854
[No Abstract] [Full Text] [Related]
9. Rheumatoid arthritis therapy: the slow-acting agents.
Hardin JG
Hosp Pract (Off Ed); 1989 Jun; 24(6):163-8, 170, 173-8. PubMed ID: 2566617
[No Abstract] [Full Text] [Related]
10. Which component of sulphasalazine is active in rheumatoid arthritis?
Pullar T; Hunter JA; Capell HA
Br Med J (Clin Res Ed); 1985 May; 290(6481):1535-8. PubMed ID: 2860942
[TBL] [Abstract][Full Text] [Related]
11. Does sulphasalazine cause drug induced systemic lupus erythematosus? No effect evident in a prospective randomised trial of 200 rheumatoid patients treated with sulphasalazine or auranofin over five years.
Gordon MM; Porter DR; Capell HA
Ann Rheum Dis; 1999 May; 58(5):288-90. PubMed ID: 10225813
[TBL] [Abstract][Full Text] [Related]
12. Sulphasalazine treatment in rheumatoid arthritis.
Bax DE; Greaves MS; Amos RS
J Rheumatol; 1986 Apr; 13(2):463-4. PubMed ID: 2873249
[No Abstract] [Full Text] [Related]
13. Rheumatoid arthritis.
Emery P; Suarez-Almazor M
Clin Evid; 2003 Jun; (9):1349-71. PubMed ID: 15366179
[No Abstract] [Full Text] [Related]
14. Ten years of sulphasalazine use in rheumatoid arthritis.
McConkey B
Br J Rheumatol; 1989 Apr; 28(2):175-6. PubMed ID: 2565130
[No Abstract] [Full Text] [Related]
15. Auranofin in rheumatoid arthritis: what variables could affect the clinical response?
Harth M
Agents Actions Suppl; 1988; 24():167-77. PubMed ID: 3055876
[No Abstract] [Full Text] [Related]
16. Adverse interaction between intramuscular methylprednisolone and sulphasalazine in patients with early rheumatoid arthritis. A pilot study.
Gough A; Sheeran T; Arthur V; Panayi G; Emery P
Scand J Rheumatol; 1994; 23(1):46-8. PubMed ID: 7906428
[TBL] [Abstract][Full Text] [Related]
17. Effects of antirheumatic treatment on gastric secretory function and salivary flow in patients with rheumatoid arthritis.
Kanerud L; Hafström I; Berg A
Clin Exp Rheumatol; 1991; 9(6):595-601. PubMed ID: 1684921
[TBL] [Abstract][Full Text] [Related]
18. HLA-B27 related arthritis, sulphasalazine and rheumatoid arthritis.
Sheldon P
Br J Rheumatol; 1987 Oct; 26(5):321-4. PubMed ID: 2889499
[No Abstract] [Full Text] [Related]
19. Sulphasalazine in the treatment of rheumatoid arthritis.
Pelísková Z; Vácha J; Trnavský K
Z Rheumatol; 1985; 44(6):263-6. PubMed ID: 2869625
[TBL] [Abstract][Full Text] [Related]
20. Auranofin and quality of life.
Morgan GJ
Scand J Rheumatol; 1988; 17(5):363. PubMed ID: 3212406
[No Abstract] [Full Text] [Related]
[Next] [New Search]
